Status:
COMPLETED
VO2max & HRQoL in Children With Sickle Cell Disease
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Sickle Cell
Children
Eligibility:
All Genders
6-17 years
Brief Summary
Sickle cell disease is the most common inherited genetic disorder, accounting for 300,000 births worldwide per year. It is caused by an autosomal recessive mutation of the β-globin gene, responsible f...
Detailed Description
This prospective case-control study included sickle cell children and healthy controls from 6 to 17 years old. Patients refuse the use of medical data will be excluded. After description of the study...
Eligibility Criteria
Inclusion
- Sickle cell children
- Child from 6 to 17 years old, with a confirmed diagnosis of sickle cell disease (i.e., homozygous HbS/S or heterozygous HbS/C mutations), during their routine follow-up, having performed :
- a hematology consultation : physical examination, blood test
- a cardiology consultation : electrocardiogram, transthoracic echocardiography
- a respiratory plethysmography
- a CPET and to fill in the study questionnaires.
Exclusion
- Parents' refusal to use medical data.
- Healthy children
- Inclusion Criteria:
- Child from 6 to 17 years old having performed a cardio-respiratory exercise test for chest pain, dyspnea on exertion, heart murmur and whose results do not find:
- Congenital heart disease (normal echocardiography and ECG)
- Respiratory disease (normal FEV1 and FVC)
- Child having performed a maximal cardio-respiratory stress exercise until exhaustion.
Key Trial Info
Start Date :
November 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2022
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT05995743
Start Date
November 1 2021
End Date
November 1 2022
Last Update
August 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pediatric and Congenital Cardiology Department, Arnaud De Villeneuve University Hospital
Montpellier, Occitanie, France, 34295